
The pharmaceutical sector witnesses inelastic demand for its products owing to the rise of chronic diseases and an aging population. Given the solid prospects of the pharmaceutical industry, it could be wise to buy the fundamentally strong pharmaceutical giant Pfizer Inc. (PFE).
During the first quarter, PFE surpassed the EPS and revenue estimates. Its EPS came 24.7% above the analyst estimate, while its revenue beat the consensus estimate by 10.9%.